• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    12/6/24 4:05:57 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CABA alert in real time by email
    SC 13G/A 1 d608868dsc13ga.htm CABALETTA BIO, INC. Cabaletta Bio, Inc.

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Cabaletta Bio, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    12674W109

    (CUSIP Number)

    November 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 12674W109

     

     1.   

     Names of Reporting Persons

     

     Alger Associates, Inc. 13-3017981

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     New York

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.   

     Sole Voting Power

     

     1,326,193

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     1,326,193

       8.  

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,326,193

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     2.7%

    12.  

     Type of Reporting Person (See Instructions)

     

     HC

     

    2


    Item 1.      
       (a)    Name of Issuer
         

    Cabaletta Bio, Inc.

       (b)   

    Address of Issuer’s Principal Executive Offices

    2929 Arch Street, Suite 600

    Philadelphia, PA 19104

    Item 2.      
       (a)    Name of Person Filing
         

    Alger Associates, Inc.

       (b)    Address of Principal Business Office or, if none, Residence
         

    100 Pearl Street, 27th Floor, New York, NY 10004

       (c)    Citizenship
         

    New York

       (d)    Title of Class of Securities
         

    Common Stock

       (e)    CUSIP Number
         

    12674W109

    Item 3.    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       (a)   

    ☐   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

       (b)   

    ☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

       (c)   

    ☐   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

       (d)   

    ☐   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

       (e)   

    ☐   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

       (f)   

    ☐   An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

       (g)   

    ☒   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

       (h)   

    ☐   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

       (i)   

    ☐   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

       (j)   

    ☐   A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);

       (k)   

    ☐   Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:        

     

    3


    Item 4.    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

       (a)    Amount beneficially owned:
         

    1,326,193

       (b)    Percent of class:
         

    2.7%

       (c)    Number of shares as to which the person has:
         

      

          (i)    Sole power to vote or to direct the vote
            

    1,326,193

          (ii)    Shared power to vote or to direct the vote
            

    0

          (iii)    Sole power to dispose or to direct the disposition of
            

    1,326,193

          (iv)    Shared power to dispose or to direct the disposition of
            

    0

     

    Item 5.   Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.
    Item 6.   Ownership of More than Five Percent on Behalf of Another Person
    The securities reported herein are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC (“FAM”), a registered investment adviser. FAM is a 100% owned subsidiary of Alger Group Holdings, LLC (“AGH”), a holding company. AGH is a 100% owned subsidiary of Alger Associates, Inc., a holding company.
    Item 7.   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
    See Exhibit A
    Item 8.   Identification and Classification of Members of the Group
    Item 9.   Notice of Dissolution of Group
    Item 10.   Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    4


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    By:   Alger Associates, Inc.
    By:  

    /s/ Hal Liebes

    Name:   Hal Liebes
    Title:   Secretary
    Date:   December 6, 2024

     

    5


    Exhibit A

    Subsidiary

    Alger Group Holdings, LLC — HC

    Fred Alger Management, LLC — IA

    Get the next $CABA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CABA

    DatePrice TargetRatingAnalyst
    12/20/2024$15.00 → $6.00Outperform → In-line
    Evercore ISI
    12/19/2024$12.00 → $6.00Overweight → Equal Weight
    Wells Fargo
    10/10/2024$10.00Buy
    UBS
    2/5/2024$36.00Buy
    Jefferies
    11/29/2023$38.00Outperform
    William Blair
    10/24/2023$40.00Overweight
    Cantor Fitzgerald
    10/19/2023$31.00Buy
    Stifel
    9/5/2023$22.00Buy
    Citigroup
    More analyst ratings

    $CABA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cabaletta Bio downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Cabaletta Bio from Outperform to In-line and set a new price target of $6.00 from $15.00 previously

      12/20/24 7:29:05 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Cabaletta Bio from Overweight to Equal Weight and set a new price target of $6.00 from $12.00 previously

      12/19/24 7:31:17 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • UBS initiated coverage on Cabaletta Bio with a new price target

      UBS initiated coverage of Cabaletta Bio with a rating of Buy and set a new price target of $10.00

      10/10/24 7:27:43 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care